Qualisys Holding AB hereby publishes the Interim Report for the period July 1 – September 30, 2026. The Report is available as an attached file to this release and on Qualisys website. Below is a summary of the report.
The third quarter marked an important milestone. Our markerless strategy moved from development into commercial reality. OnTraq signed its first agreements with elite clubs in both the Premier League and the NFL, and we pre-launched Prisma Pose for our installed base of biomechanics labs.
As announced in our preliminary results on 20 October, net sales fell short of our expectations, mainly due to delayed orders. EBIT reflects both lower volumes and commercialisation costs in markerless technology. Gross margin improved to 72.2 percent (70.7). Order intake was in line with the same period last year and followed our usual seasonal pattern.
OnTraq's subscription-based model adds recurring revenue that complements our project-based business. We are in final discussions with additional teams in Europe and North America. Together with Prisma Pose and our partnership with Theia, we now meet customer needs from the training ground to the clinic and the research lab.
The fourth quarter is historically our strongest, and our priorities are clear: convert delayed projects into orders, at the same time roll out Prisma Pose across our installed base, sign more OnTraq teams, and strengthen our position in selected engineering application areas. Our financial targets over a business cycle are unchanged.
Third Quarter (July-September)
First Nine Months of 2026 (January-September)